Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 18/20 | 0.47 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | TTK | P33981 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4536590 | 0.90 | LRRK2 (0.47) | LRRK2SLC34A1NPC1RAB9ACYP1A2 | |
| SCHEMBL4541785 | 0.80 | LRRK2 (0.58) | LRRK2CYP1A2TTK | |
| SCHEMBL9930214 | 0.80 | LRRK2 (0.47) | LRRK2CYP1A2TTK | |
| SCHEMBL4542042 | 0.80 | LRRK2 (0.47) | LRRK2CYP1A2TTK | |
| SCHEMBL4542804 | 0.79 | LRRK2 (0.48) | LRRK2CYP1A2TTK | |
| SCHEMBL15528082 | 0.77 | LRRK2 (0.73) | LRRK2CYP1A2TTK | |
| SCHEMBL5020930 | 0.76 | LRRK2 (0.47) | LRRK2SLC34A1CYP1A2TTK | |
| SCHEMBL4539038 | 0.76 | LRRK2 (0.47) | LRRK2SLC34A1CYP1A2TTK | |
| SCHEMBL9288021 | 0.74 | LRRK2 (0.55) | LRRK2 | |
| SCHEMBL9281373 | 0.74 | LRRK2 (0.47) | LRRK2CYP1A2TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815882-B2 | Pyrazole aminopyrimidine derivatives as LRRK2 modulators | GENENTECH, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157427-A1 | PYRAZOLE AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | LRRK2, PARK7, PINK1 | LRRK2 1/4885SLC34A1 1310/4885NPC1 2487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.